Obesity Management

Obesity is common in CKD and drives hyperfiltration, nephron stress, and progressive kidney injury, according to experts, Kramer and Perkovic, and trial data.

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

Since 1990, the prevalence of individuals with a BMI ≥30 has increased dramatically, and without significant intervention, will continue to do so.

Frikke-Schmidt discusses the newfound genetic correlation between vascular-related dementia and an increased BMI, partially mediated by high blood pressure.

The investigational dual GLP-1/GIP receptor agonist resulted in substantial weight loss without plateau after 48 weeks in patients with obesity.

Weintraub discusses how patients with overweight or obesity, regardless of T2D, will regain weight in varying degrees after discontinuing therapy.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clearances, in this week’s essential news roundup.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Susan Weiner, MS, to discuss the recently released US Dietary Guidelines.

An FDA review found no increased risk of SI/B associated with the use of GLP-1 RA medications, including liraglutide, semaglutide, and tirzepatide.

These recommendations simultaneously emphasize the efficacy of weight loss drugs and encourage incorporating lifestyle therapy on top of medication.

A new national database study suggests malnutrition reverses the obesity survival benefit in hospitalized ESKD patients undergoing dialysis

A trio of professional societies voice concerns about certain elements of the Dietary Guidelines for Americans, 2025–2030, and their potential negative health impacts.

The Q4 recap for endocrinology spotlights major FDA decisions, updates to diabetes care standards, and key clinical trial updates.

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the groundbreaking news of oral semaglutide's approval and its cardioprotective benefits.

The approval is based on the 64-week phase 3 OASIS 4 trial showing an average weight loss of ~17% if all patients stayed on treatment with semaglutide and ~14% regardless of if patients stayed on treatment.

Singhal discusses the multi-pronged impact of the Commission’s definition of obesity and how it effects clinicians, patients, and the treatment structure itself.

Results from the ATTAIN-MAINTAIN phase 3 study have displayed orforglipron’s efficacy in maintaining weight loss without major safety concerns.

Experts redefine obesity, distinguishing between preclinical and clinical forms, aiming to improve diagnosis and treatment strategies for better health outcomes.

GLP-1 medications are revolutionizing treatment for neurological conditions.

Findings from the CARE feasibility RCT show the safety, feasibility, and likely cost-effectiveness of intentional weight loss before colorectal cancer surgery.

Catch up with major trial results, key clinician insights, and more.

Shagun Bindlish, MD, emphasizes the urgent need to integrate diabetes and obesity care, addressing their shared metabolic roots for better health outcomes.

The investigational unimolecular GLP-1 and amylin receptor agonist substantially improved weight loss in a phase 2 trial.